Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2634

1.

A new step towards an HIV/AIDS vaccine.

Pavlakis GN, Felber BK.

Lancet. 2018 Jul 21;392(10143):192-194. doi: 10.1016/S0140-6736(18)31548-4. Epub 2018 Jul 6. No abstract available.

PMID:
30047374
2.

Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.

Chan KW, Pan R, Costa M, Gorny MK, Wang S, Lu S, Kong XP.

J Virol. 2018 Aug 29;92(18). pii: e00641-18. doi: 10.1128/JVI.00641-18. Print 2018 Sep 15.

PMID:
29997214
3.

Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.

Hovanessian AG, Soundaramourty C, Benferhat R, Le Grand R, Dereuddre-Bosquet N, Krust B, Estaquier J.

J Virol. 2018 Aug 29;92(18). pii: e00370-18. doi: 10.1128/JVI.00370-18. Print 2018 Sep 15.

PMID:
29976675
4.

HIV cure: global overview of bNAbs' patents and related scientific publications.

Possas C, Antunes AMS, Lins Mendes FM, Veloso V, Martins RM, Homma A.

Expert Opin Ther Pat. 2018 Jul;28(7):551-560. doi: 10.1080/13543776.2018.1495708. Review.

PMID:
29962249
5.

Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development.

Niessl J, Kaufmann DE.

Viruses. 2018 Jun 19;10(6). pii: E336. doi: 10.3390/v10060336. Review.

6.

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.

Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F, de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N; RV305 Study Group.

PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018.

7.

Natural Immunity to HIV: A Template for Vaccine Strategies.

Fourcade L, Poudrier J, Roger M.

Viruses. 2018 Apr 23;10(4). pii: E215. doi: 10.3390/v10040215. Review.

8.

HIV Vaccination: A Roadmap among Advancements and Concerns.

Trovato M, D'Apice L, Prisco A, De Berardinis P.

Int J Mol Sci. 2018 Apr 19;19(4). pii: E1241. doi: 10.3390/ijms19041241. Review.

9.

Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro.

Ozorowski G, Cupo A, Golabek M, LoPiccolo M, Ketas TA, Cavallary M, Cottrell CA, Klasse PJ, Ward AB, Moore JP.

J Virol. 2018 Jun 13;92(13). pii: e00381-18. doi: 10.1128/JVI.00381-18. Print 2018 Jul 1.

10.

The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.

Ringel O, Vieillard V, Debré P, Eichler J, Büning H, Dietrich U.

Viruses. 2018 Apr 15;10(4). pii: E197. doi: 10.3390/v10040197. Review.

11.

Advances in HIV-1 Vaccine Development.

Gao Y, McKay PF, Mann JFS.

Viruses. 2018 Apr 1;10(4). pii: E167. doi: 10.3390/v10040167. Review.

12.

DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity.

Ajamian L, Melnychuk L, Jean-Pierre P, Zaharatos GJ.

Viruses. 2018 Feb 27;10(3). pii: E100. doi: 10.3390/v10030100.

13.

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.

Auclair S, Liu F, Niu Q, Hou W, Churchyard G, Morgan C, Frahm N, Nitayaphan S, Pitisuthithum P, Rerks-Ngarm S, Kimata JT, Soong L, Franchini G, Robb M, Kim J, Michael N, Hu H.

PLoS Pathog. 2018 Feb 23;14(2):e1006888. doi: 10.1371/journal.ppat.1006888. eCollection 2018 Feb.

14.

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.

Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Alam SM, Montefiori DC, Tomaras GD.

J Virol. 2018 Mar 28;92(8). pii: e01843-17. doi: 10.1128/JVI.01843-17. Print 2018 Apr 15.

15.

Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Hurwitz JL, Bonsignori M.

Viral Immunol. 2018 Mar;31(2):124-132. doi: 10.1089/vim.2017.0144. Epub 2018 Jan 9. Review.

PMID:
29315059
16.

Prevention Strategies Against HIV Transmission: A Proactive Approach.

Carrion AJ, Miles JD, Mosley JF, Smith LL, Prather AS, Gurley MM Jr, Phan LD, Everton EC.

J Pharm Pract. 2018 Feb;31(1):82-90. doi: 10.1177/0897190017696946. Epub 2017 Mar 21. Review.

PMID:
29278971
17.

Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples.

Liechti T, Kadelka C, Ebner H, Friedrich N, Kouyos RD, Günthard HF, Trkola A.

J Immunol Methods. 2018 Mar;454:48-58. doi: 10.1016/j.jim.2017.12.003. Epub 2017 Dec 22.

18.

Hot News: HIV Epidemics - Current Burden and Future Prospects.

de Mendoza C.

AIDS Rev. 2017 Oct-Dec;19(4):239.

PMID:
29271972
19.

Systems serology: profiling vaccine induced humoral immunity against HIV.

Chung AW, Alter G.

Retrovirology. 2017 Dec 21;14(1):57. doi: 10.1186/s12977-017-0380-3. Review.

20.

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.

Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR.

J Virol. 2018 Feb 12;92(5). pii: e01796-17. doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.

Supplemental Content

Loading ...
Support Center